ArticleCancer2024

Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study.

Francesca Palandri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.